---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-049544"
form_type: "8-K"
ticker: "SCYX"
cik: "0001178253"
company_name: "SCYNEXIS INC"
filed_at: "2023-09-25T23:59:59+00:00"
generated_at: "2026-06-10T09:09:15.726291+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# SCYNEXIS recalls BREXAFEMME and pauses Phase 3 MARIO study on cross-contamination risk

## Summary
- GSK review found a beta-lactam drug manufactured on equipment shared with ibrexafungerp; potential cross-contamination risk.
- No known contamination of ibrexafungerp and no adverse events reported; recall is out of caution.
- Market recall of BREXAFEMME (ibrexafungerp tablets) and temporary hold on all clinical studies, including Phase 3 MARIO.
- Mitigation strategy and resupply plan to be determined; ongoing collaboration with GSK.

## SEC filing metadata
- accession: 0000950170-23-049544
- form_type: 8-K
- ticker: SCYX
- cik: 0001178253
- company_name: SCYNEXIS INC
- filed_at: 2023-09-25T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178253/000095017023049544/0000950170-23-049544-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178253/000095017023049544/scyx-20230919.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-049544
- JSON: https://secwatch.observer/filing/0000950170-23-049544.json
- Plain text: https://secwatch.observer/filing/0000950170-23-049544.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.